Alcohol use disorder (AUD) affects a substantial number of people worldwide — making it one of the most prevalent and treatment-resistant substance use disorders. Ibogaine, a psychoactive alkaloid derived from the Tabernanthe iboga plant, is attracting growing research interest as a potential intervention for AUD, particularly for people who have not responded to conventional treatments.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

What the Research Shows

Clinical evidence for ibogaine specifically in alcohol use disorder remains limited, with no large-scale randomized controlled trials published to date. The majority of existing evidence comes from case reports, observational studies, and retrospective surveys conducted at clinics operating outside the United States — primarily in Mexico, the Netherlands, Canada, and New Zealand.

One of the most cited observational studies in the ibogaine literature is Mash DC et al. (2018), published in Frontiers in Pharmacology. Conducted at a clinic in St. Kitts, this open-label case series enrolled 191 patients treated for opioid and cocaine dependence. While the primary focus was not alcohol, the study demonstrated an acceptable safety profile across a diverse clinical population under medical supervision, with no serious adverse events reported in the study cohort — informing broader understandings of ibogaine's tolerability in substance use contexts.

For alcohol specifically, preclinical evidence has been more informative. Multiple animal studies — including work from Glick SD and colleagues on ibogaine and its analog 18-MC — have demonstrated reductions in voluntary alcohol consumption in rodent models. These studies suggest ibogaine may modulate dopaminergic and serotonergic reward pathways that underlie alcohol craving and compulsive drinking behavior.

A retrospective online survey published in Drug and Alcohol Dependence (Kohek et al., 2023) examined self-reported outcomes among individuals who had used ibogaine for AUD. The survey found that many respondents reported significant reductions in alcohol cravings and consumption following treatment, though the study's self-selected sample and reliance on self-report limit its conclusions. This type of survey evidence, while useful for hypothesis generation, cannot establish causality.

Case report data and qualitative research from ibogaine clinics consistently describe a pattern in which patients report an abrupt interruption of compulsive alcohol use, frequently accompanied by oneirogenic (dream-like visionary) experiences that participants describe as psychologically meaningful and linked to sustained motivation for abstinence. Researchers have proposed that ibogaine's combination of pharmacological action and psychological experience may jointly contribute to outcomes in AUD — though this mechanism has not been rigorously tested in controlled trials.

Clinical Trial Results

No Phase II or Phase III randomized controlled trials specifically targeting alcohol use disorder with ibogaine have been completed and published. The table below reflects the best available clinical evidence relevant to ibogaine in substance use disorders more broadly:

Trial / Study Design N Key Outcome Year
Mash DC et al. — St. Kitts clinic (opioid/cocaine) Open-label case series 191 No serious adverse events; reductions in substance use reported across sample 2018
Alper KR et al. — opioid case series Case series 33 25 of 33 completed opioid detox without withdrawal medications 1999
Noller GE et al. — New Zealand opioid pilot Prospective observational 14 Significant reduction in ASI-Lite drug use scores at 12 months; one patient death 2018
Kohek et al. — retrospective survey (AUD focus) Online retrospective survey Not confirmed Self-reported reductions in alcohol cravings and use; self-selected sample 2023

Note: No studies in this table were specifically designed as controlled trials for alcohol use disorder. The Kohek et al. entry reflects survey-level evidence only. All substance use disorder studies above were conducted primarily in opioid or mixed populations.

How Ibogaine May Help

Researchers have proposed several overlapping mechanisms by which ibogaine might reduce alcohol use and craving, though none has been definitively confirmed in human clinical trials for AUD:

Dopamine System Reset

Chronic alcohol use dysregulates the mesolimbic dopamine system — the brain's primary reward circuit. Ibogaine and its primary metabolite noribogaine interact with sigma-2 receptors and influence dopamine transporter function in ways that may help normalize reward signaling. Preclinical rodent studies, including work by Glick and colleagues, suggest this contributes to reduced motivational salience of alcohol.

Serotonin Modulation

Ibogaine acts as a serotonin reuptake inhibitor and agonist at certain serotonin receptor subtypes. Serotonergic dysregulation is implicated in impulsivity, mood instability, and craving — all of which contribute to compulsive alcohol use. Modulating this system may reduce the emotional drivers of relapse.

NMDA Receptor Antagonism

Alcohol's physical dependence is partly driven by NMDA receptor upregulation during withdrawal. Ibogaine's NMDA antagonist properties may help buffer this rebound — potentially reducing the severity of acute withdrawal symptoms and the neurological kindling that makes repeated withdrawals progressively more dangerous.

Opioid System Interactions

Ibogaine interacts with kappa and mu opioid receptors. The endogenous opioid system plays a role in the rewarding effects of alcohol — a mechanism already exploited by naltrexone, an approved AUD medication. Ibogaine's interaction with this system may partly overlap with naltrexone's mechanism, though the profile is substantially different.

Psychological and Introspective Effects

The extended psychedelic experience produced by ibogaine (typically lasting 12–36 hours) is described by many patients as a profound opportunity for self-examination. Research in adjacent psychedelic therapies suggests that such experiences — particularly when accompanied by therapeutic support — can catalyze insight into addictive patterns, increase motivation for change, and promote psychological flexibility. Whether these psychological effects are necessary, sufficient, or merely additive in AUD outcomes remains an open question.

Limitations and What We Don't Know Yet

Honest evaluation of the evidence requires acknowledging significant gaps:

  • No randomized controlled trials for AUD specifically. Every piece of human evidence for ibogaine in alcohol use disorder is observational, retrospective, or survey-based. Without randomization and control conditions, it is impossible to separate ibogaine's effects from expectation, selection bias, the therapeutic context, or spontaneous remission.
  • Self-selected populations skew outcomes. Most people accessing ibogaine treatment are highly motivated, financially able to travel abroad, and have often failed multiple prior treatments. Outcomes in this group may not generalize to the broader AUD population.
  • Optimal dosing for AUD is unknown. Unlike opioid withdrawal — where protocols have been informally standardized across clinics — dosing for alcohol use disorder lacks clinical consensus. This creates variability in both efficacy and safety.
  • Interaction with alcohol withdrawal physiology is poorly understood. Alcohol withdrawal syndrome (AWS) can be life-threatening, involving seizures and delirium tremens. Ibogaine's effects on the CNS during active or recent withdrawal have not been adequately studied. The risk of dangerous interactions — including lowered seizure threshold and cardiac stress — has not been formally characterized.
  • Long-term follow-up data is sparse. Most available AUD-related reports describe outcomes at one to three months. Relapse rates beyond six months in ibogaine-treated AUD patients are essentially unknown.
  • No biomarkers or predictors of response. Researchers do not yet know which patients with AUD are most likely to benefit, nor have genetic, neurological, or psychological predictors of response been identified in this population.
  • Regulatory and access barriers limit research. Ibogaine remains a Schedule I controlled substance in the United States, creating significant obstacles to conducting clinical trials. Most human data comes from unregulated clinic settings, making quality control and data integrity difficult to verify.

Safety Considerations

Safety concerns for ibogaine are significant and are amplified by specific features of alcohol use disorder:

Cardiac Risk

Ibogaine prolongs the cardiac QT interval, which can trigger potentially fatal arrhythmias — particularly torsades de pointes. This risk applies to all patients but is compounded in individuals with alcohol-related cardiomyopathy, electrolyte imbalances (common in heavy drinkers), or who are taking QT-prolonging medications. Baseline ECG, electrolyte panels, and cardiac risk screening are considered essential before any ibogaine treatment. Co-administration of intravenous magnesium — used in the Stanford/VETS veterans study — has been proposed as a risk mitigation strategy, though this has not been studied specifically in AUD populations.

Seizure Risk During Alcohol Withdrawal

This is a critical and under-studied concern. Alcohol withdrawal is one of the few withdrawal syndromes that can be directly fatal, partly due to seizure risk. Ibogaine may lower seizure threshold, and combining the two neurological stressors — alcohol withdrawal and a high-dose psychoactive agent — poses unknown but potentially serious risks. Many ibogaine clinicians require patients to be medically stabilized from alcohol withdrawal before administering ibogaine, though protocols vary widely.

Dehydration and Electrolyte Imbalance

Ibogaine treatment frequently causes nausea, vomiting, and prolonged immobility. In individuals with compromised nutritional status — common in severe AUD — this can exacerbate electrolyte disturbances that themselves increase cardiac and neurological risk.

Liver Function

Ibogaine is metabolized hepatically. Alcohol-related liver disease, ranging from fatty liver to cirrhosis, is prevalent in people with long-term AUD. Impaired liver metabolism of ibogaine may lead to elevated plasma levels and prolonged drug exposure, increasing the risk of toxicity. Liver function testing is generally considered a prerequisite for treatment.

Drug Interactions

Many individuals with AUD are prescribed medications including benzodiazepines, antidepressants, or antipsychotics — several of which have independent QT-prolonging properties or interact with ibogaine's metabolic pathways. Medication washout periods and careful pharmacological review are essential.

Fatalities

Ibogaine-related fatalities have been documented in the medical literature, predominantly attributed to cardiac arrhythmia, often in the context of inadequate screening, polysubstance use, or unrecognized medical comorbidities. A comprehensive review by Koenig and Hilber (2015) catalogued dozens of ibogaine-associated deaths globally. In the New Zealand observational study by Noller et al. (2018), one patient death occurred. These risks are not theoretical.

Current Treatment Landscape

Alcohol use disorder has several FDA-approved pharmacological treatments, which provide important context for evaluating ibogaine's potential role:

  • Naltrexone (oral and extended-release injectable): Reduces the rewarding effects of alcohol via opioid receptor blockade. Moderate evidence base; under-prescribed in clinical practice.
  • Acamprosate: Modulates glutamate and GABA systems to reduce post-acute withdrawal discomfort and craving. Approved for maintaining abstinence.
  • Disulfiram: Creates an aversive physical reaction to alcohol consumption. Effective for highly motivated patients with strong external accountability structures; poor adherence limits real-world efficacy.
  • Psychosocial treatments: Cognitive behavioral therapy (CBT), motivational enhancement therapy, and 12-step facilitation have robust evidence bases.

Despite these options, AUD remains substantially undertreated. Fewer than 10% of people with AUD receive any medication-based treatment. Relapse rates are high across all existing therapies, with anecdotal evidence and clinical observation suggesting recurrence within the first year of treatment is common. This treatment gap is part of what motivates interest in novel approaches, including ibogaine.

Ibogaine's proposed niche — if clinical evidence eventually supports it — would likely be as an intervention for treatment-resistant AUD, offering a potential neurological and psychological reset that existing daily oral medications do not provide. However, it cannot currently be recommended over evidence-based treatments, and should not be considered a substitute for them.

Regulatory momentum is growing: several countries including Australia and Canada have moved toward regulated psychedelic therapy frameworks. In the United States, ibogaine remains Schedule I, though research programs at institutions including Stanford University have created pathways for study in adjacent populations. Dedicated AUD trials will require sustained regulatory engagement and funding.

Frequently Asked Questions

No. Ibogaine is not approved for any medical use in the United States, where it remains a Schedule I controlled substance. No regulatory agency — including the FDA — has approved ibogaine for alcohol use disorder. People who receive ibogaine for AUD currently do so at clinics operating in countries where ibogaine is legal or unscheduled, such as Mexico, the Netherlands, and some other jurisdictions.
Preclinical research and self-report surveys suggest ibogaine may reduce alcohol craving, potentially through effects on dopamine and serotonin systems involved in reward processing. However, no controlled human clinical trial has tested ibogaine's effect on alcohol cravings as a primary outcome. The available human evidence comes from retrospective surveys and case reports, which cannot establish causality. Rigorous clinical trials are needed before any conclusions can be drawn.
This is a major unresolved safety concern. Alcohol withdrawal syndrome can be life-threatening, with risks including seizures and delirium tremens. Ibogaine itself may lower seizure threshold and places significant stress on the cardiovascular system. Most experienced ibogaine practitioners require patients to be medically stabilized from acute alcohol withdrawal — typically with benzodiazepine-assisted detox — before administering ibogaine. However, protocols vary widely across clinics, and the safety of ibogaine in recently alcohol-dependent individuals has not been formally studied in controlled settings.
Naltrexone and acamprosate have robust, replicated evidence from randomized controlled trials and are FDA-approved for AUD. Ibogaine has no completed randomized controlled trials for AUD. The two categories are not clinically comparable at this stage of evidence. That said, ibogaine's proposed mechanism — a single-dose intervention that may produce sustained neurological and psychological change — is conceptually different from daily maintenance medications. If ibogaine eventually demonstrates efficacy in trials, it would likely be considered for treatment-resistant cases or as a complement to existing care, not a replacement for evidence-based treatments.
People with alcohol use disorder face several heightened risks with ibogaine. Cardiac risk is elevated by alcohol-related cardiomyopathy and electrolyte imbalances common in heavy drinkers. Seizure risk may be compounded by alcohol withdrawal physiology. Liver disease — prevalent in long-term AUD — can impair ibogaine metabolism, potentially raising plasma drug levels to dangerous concentrations. Nutritional deficiencies, particularly thiamine deficiency (associated with Wernicke-Korsakoff syndrome), may also be relevant. Thorough medical screening — including ECG, liver function tests, electrolytes, and cardiac evaluation — is essential before any ibogaine treatment is considered.
Dedicated Phase II or Phase III randomized controlled trials of ibogaine specifically for alcohol use disorder are not yet established in the published literature. Research activity is growing — particularly in Canada, where ibogaine research has received regulatory support, and at academic institutions exploring psychedelic-assisted therapies more broadly. Anyone interested in participating in research should check ClinicalTrials.gov for currently recruiting studies, as the landscape is evolving rapidly. Ibogaine's Schedule I status in the US continues to restrict domestic trial development.
Ibogaine is typically administered in a single high-dose session, lasting 12–36 hours, sometimes followed by lower booster doses. Unlike opioid withdrawal — where ibogaine's acute anti-withdrawal effects are pharmacologically direct — alcohol use disorder involves a more complex set of craving, reward, and psychological drivers. Some clinic reports and patient accounts suggest a single session can produce meaningful reductions in alcohol use, but durability of effect, the role of integration therapy, and whether multiple sessions improve outcomes are all unstudied questions in this population. Single-session results in the absence of ongoing psychosocial support are generally considered insufficient for long-term recovery from AUD.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.